Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
BUSINESS
Enspryng Reduces Risk and Severity of Relapse by 79% in NMOSD Patients: Chugai
Chugai Pharmaceutical said on September 10 that a post-hoc analysis of global PIII studies found that Enspryng (satralizumab), a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody, reduced the risk and severity of relapse by 79% compared to placebo in patients…
To read the full story
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





